Cite
HARVARD Citation
Dall, P. et al. (2017). Trastuzumab in Human Epidermal Growth Factor Receptor 2‐Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany. Oncologist. pp. 131-138. [Online].